These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 31590120)

  • 1. New and emerging anti-fibrotic therapeutics entering or already in clinical trials in chronic liver diseases.
    Lemoinne S; Friedman SL
    Curr Opin Pharmacol; 2019 Dec; 49():60-70. PubMed ID: 31590120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic Steatohepatitis (NASH) and Hepatic Fibrosis: Emerging Therapies.
    Wattacheril J; Issa D; Sanyal A
    Annu Rev Pharmacol Toxicol; 2018 Jan; 58():649-662. PubMed ID: 29058997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis.
    Noureddin M; Anstee QM; Loomba R
    Aliment Pharmacol Ther; 2016 Jun; 43(11):1109-23. PubMed ID: 27061197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histological evaluation of nintedanib in non-alcoholic steatohepatitis mice.
    Susutlertpanya W; Wakuda H; Otani N; Kuramoto T; Li L; Kuranari M; Sekiguchi A; Kudo H; Uchida T; Imai H; Uemura N
    Life Sci; 2019 Jul; 228():251-257. PubMed ID: 31078545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Cell Death and Sterile Inflammation Loop for the Treatment of Nonalcoholic Steatohepatitis.
    Wree A; Mehal WZ; Feldstein AE
    Semin Liver Dis; 2016 Feb; 36(1):27-36. PubMed ID: 26870930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specialized Proresolving Mediators: Enhancing Nonalcoholic Steatohepatitis and Fibrosis Resolution.
    Musso G; Gambino R; Cassader M; Paschetta E; Sircana A
    Trends Pharmacol Sci; 2018 Apr; 39(4):387-401. PubMed ID: 29499974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Will Studies in Nonalcoholic Steatohepatitis Help Manage Alcoholic Steatohepatitis?
    Sundaram V; Morgan TR
    Clin Liver Dis; 2019 Feb; 23(1):157-165. PubMed ID: 30454829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baicalin attenuates non-alcoholic steatohepatitis by suppressing key regulators of lipid metabolism, inflammation and fibrosis in mice.
    Zhang J; Zhang H; Deng X; Zhang N; Liu B; Xin S; Li G; Xu K
    Life Sci; 2018 Jan; 192():46-54. PubMed ID: 29158052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scoparone alleviates inflammation, apoptosis and fibrosis of non-alcoholic steatohepatitis by suppressing the TLR4/NF-κB signaling pathway in mice.
    Liu B; Deng X; Jiang Q; Li G; Zhang J; Zhang N; Xin S; Xu K
    Int Immunopharmacol; 2019 Oct; 75():105797. PubMed ID: 31421545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Chow MD; Lee YH; Guo GL
    Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In search of the magic bullet: can liver inflammation and fibrosis be reversed with medications?
    Zimmermann HW; Tacke F
    Expert Rev Gastroenterol Hepatol; 2015; 9(9):1139-41. PubMed ID: 26138749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [What is the (right) target for non-alcoholic fatty liver disease (NAFLD)?].
    Huber Y; Galle PR; Schattenberg JM
    Z Gastroenterol; 2020 Jan; 58(1):68-73. PubMed ID: 31931543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies.
    Musso G; Cassader M; Gambino R
    Nat Rev Drug Discov; 2016 Apr; 15(4):249-74. PubMed ID: 26794269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease.
    Imprialos K; Stavropoulos K; Bouloukou S; Kerpiniotis G; Karagiannis A; Doumas M
    Curr Vasc Pharmacol; 2018; 16(3):276-288. PubMed ID: 28676020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Future trends in the treatment of non-alcoholic steatohepatitis.
    Fiorucci S; Biagioli M; Distrutti E
    Pharmacol Res; 2018 Aug; 134():289-298. PubMed ID: 30021122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis.
    Krenkel O; Puengel T; Govaere O; Abdallah AT; Mossanen JC; Kohlhepp M; Liepelt A; Lefebvre E; Luedde T; Hellerbrand C; Weiskirchen R; Longerich T; Costa IG; Anstee QM; Trautwein C; Tacke F
    Hepatology; 2018 Apr; 67(4):1270-1283. PubMed ID: 28940700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH).
    Goto R; Kamimura K; Shinagawa-Kobayashi Y; Sakai N; Nagoya T; Niwa Y; Ko M; Ogawa K; Inoue R; Yokoo T; Sakamaki A; Kamimura H; Abe S; Nishina H; Terai S
    FEBS Open Bio; 2019 Apr; 9(4):643-652. PubMed ID: 30984539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leveraging Clinical Pharmacology to Optimize Drug Development for Nonalcoholic Steatohepatitis and Cholestatic Liver Diseases: Workshop Report.
    Kim I; Seo S
    Clin Pharmacol Ther; 2021 Feb; 109(2):292-294. PubMed ID: 32740920
    [No Abstract]   [Full Text] [Related]  

  • 20. Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH.
    Oniciu DC; Hashiguchi T; Shibazaki Y; Bisgaier CL
    PLoS One; 2018; 13(5):e0194568. PubMed ID: 29847555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.